{"filing":{"accession_number":"0001193125-26-282048","cik":"0001921865","ticker":"ASPI","company_name":"ASP Isotopes Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"aspi-20260625.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1921865/000119312526282048/aspi-20260625.htm"},"events":[{"id":13787,"run_id":12248,"accession_number":"0001193125-26-282048","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses a proposed merger of Noble Africa LLC (ASP Isotopes' subsidiary holding Renergen Limited) with a subsidiary of ENDRA Life Sciences, with Noble Africa as the surviving entity and the combined company planning to list on Nasdaq. This is a material acquisition/change of control transaction. The concurrent $50 million private placement financing is integral to the transaction structure. The disclosure explicitly states the merger agreement terms, expected ownership structure (ASP ~89%, ENDRA ~3%, other investors ~7%), and anticipated closing in Q3-Q4 2026.","company_name":"ASP Isotopes Inc.","ticker":"ASPI","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11027,"accession_number":"0001193125-26-282048","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a proposed merger of Noble Africa LLC (ASP Isotopes' subsidiary holding Renergen Limited) with a subsidiary of ENDRA Life Sciences, with Noble Africa as the surviving entity and the combined company planning to list on Nasdaq. This is a material acquisition/change of control transaction. The concurrent $50 million private placement financing is integral to the transaction structure. The disclosure explicitly states the merger agreement terms, expected ownership structure (ASP ~89%, ENDRA ~3%, other investors ~7%), and anticipated closing in Q3-Q4 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T14:16:38.106709+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11027,"accession_number":"0001193125-26-282048","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a proposed merger of Noble Africa LLC (ASP Isotopes' subsidiary holding Renergen Limited) with a subsidiary of ENDRA Life Sciences, with Noble Africa as the surviving entity and the combined company planning to list on Nasdaq. This is a material acquisition/change of control transaction. The concurrent $50 million private placement financing is integral to the transaction structure. The disclosure explicitly states the merger agreement terms, expected ownership structure (ASP ~89%, ENDRA ~3%, other investors ~7%), and anticipated closing in Q3-Q4 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T14:16:38.106709+00:00","company_name":"ASP Isotopes Inc.","ticker":"ASPI","filing_date":"2026-06-25"}]}